Alterna Wealth Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR)

Alterna Wealth Management Inc. purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the company’s stock, valued at approximately $36,000.

Separately, JPMorgan Chase & Co. lifted its position in Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after acquiring an additional 10,754 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Price Performance

Shares of ATYR stock opened at $3.86 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The stock has a 50 day simple moving average of $3.48 and a 200-day simple moving average of $2.69. Atyr PHARMA INC has a 12-month low of $1.42 and a 12-month high of $4.22.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Equities research analysts expect that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ATYR shares. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Tuesday, December 10th. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Atyr PHARMA presently has an average rating of “Buy” and a consensus target price of $19.25.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.